Takeda Pharma Files 13D/A Amendment on Phathom Holdings

TL;DR

Takeda updated its Phathom Pharma stake filing - watch for news.

AI Summary

Takeda Pharmaceutical Co Ltd filed an amendment (No. 6) to its Schedule 13D on April 1, 2024, concerning its holdings in Phathom Pharmaceuticals, Inc. The filing indicates a change in the reporting person's intentions or beneficial ownership, though specific details on the nature of the change or the exact percentage of ownership are not provided in this excerpt.

Why It Matters

This filing signals a potential shift in Takeda's strategic interest or investment in Phathom Pharmaceuticals, which could impact Phathom's stock price and future corporate actions.

Risk Assessment

Risk Level: medium — Amendments to Schedule 13D filings often indicate significant changes in a major shareholder's position or intentions, which can lead to market volatility.

Key Players & Entities

• Takeda Pharmaceutical Co Ltd (company) — Reporting Person
• Phathom Pharmaceuticals, Inc. (company) — Issuer
• Yoshihiro Nakagawa (person) — Contact Person at Takeda
• Shashi Khiani (person) — Contact Person at Polsinelli PC

FAQ

Key Financial Figures

• $0.0001 — me of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti
• $10.70 — 02292024 Sale in Public Market 87,979 $10.70 $10.48 - $10.89 03012024 Sale in Publi
• $10.48 — 024 Sale in Public Market 87,979 $10.70 $10.48 - $10.89 03012024 Sale in Public Marke
• $10.89 — in Public Market 87,979 $10.70 $10.48 - $10.89 03012024 Sale in Public Market 95,823
• $10.67 — 03012024 Sale in Public Market 95,823 $10.67 $10.40 - $11.05 03042024 Sale in Publi
• $10.40 — 024 Sale in Public Market 95,823 $10.67 $10.40 - $11.05 03042024 Sale in Public Marke
• $11.05 — in Public Market 95,823 $10.67 $10.40 - $11.05 03042024 Sale in Public Market 58,858
• $10.36 — 03042024 Sale in Public Market 58,858 $10.36 $10.20 - $10.79 03052024 Sale in Publi
• $10.20 — 024 Sale in Public Market 58,858 $10.36 $10.20 - $10.79 03052024 Sale in Public Marke
• $10.79 — in Public Market 58,858 $10.36 $10.20 - $10.79 03052024 Sale in Public Market 50,527
• $10.22 — 03052024 Sale in Public Market 50,527 $10.22 $10.00 - $10.36 03252024 Sale in Publi
• $10.00 — 024 Sale in Public Market 50,527 $10.22 $10.00 - $10.36 03252024 Sale in Public Marke
• $10.85 — 03252024 Sale in Public Market 61,692 $10.85 $10.50 - $11.34 03262024 Sale in Publi
• $10.50 — 024 Sale in Public Market 61,692 $10.85 $10.50 - $11.34 03262024 Sale in Public Marke
• $11.34 — in Public Market 61,692 $10.85 $10.50 - $11.34 03262024 Sale in Public Market 102,696

Filing Documents

• sc13da_040124.htm (SC 13D/A) — 52KB
• 0001395064-24-000023.txt ( ) — 53KB

Interest in Securities of the Issuer

Item 1. Interest in Securities of the Issuer.

of the Prior Filing is hereby amended and restated in its entirety as follows

Item 5 of the Prior Filing is hereby amended and restated in its entirety as follows (a) See rows (11) and (13) of the cover page to this Amendment for the aggregate number of shares of Common Stock and percentage of shares of Common Stock beneficially owned by the Reporting Person. (b) See rows (11) and (13) of the cover page to this Amendment for the aggregate number of shares of Common Stock and percentage of shares of Common Stock beneficially owned by the Reporting Person. (c) Transactions in the shares of Common Stock effected by the Reporting Person during the 60 days prior to the date hereof are set forth on Schedule 1 and are incorporated herein by reference. (d) To the best knowledge of the Reporting Person, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock beneficially owned by the Reporting Person. (e) Not applicable. CUSIP No. 71722W107 Page 3 of 5 Pages SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated April 1, 2024 TAKEDA PHARMACEUTICAL COMPANY LIMITED By s Amit Singh Name Amit Singh Title Senior Vice President and Head of Treasury SCHEDULE 1 TRANSACTIONS IN THE SHARES OF COMMON STOCK BY THE REPORTING PERSON The following table sets forth all transactions in the shares of Common Stock effected by the Reporting Person during the past sixty (60) days. Unless otherwise noted below, all such transactions were effected in the open market through brokers and the price per share excludes commissions. Transaction Date Type of Transaction Number of Shares Sold Price Per Share Price Range 1 02292024 Sale in Public Market 87,979 $10.70 $10.48 - $10.89 03012024 Sale in Public Market 95,823 $10.67 $10.40 - $11.05 03042024 Sale in Public Market 58,858 $10.36 $10.20 - $10.79 03052024 Sale in Public Mark

View Full Filing

View this SC 13D/A filing on SEC EDGAR